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Abstract 
Introduction: The cost of pharmaceuticals has increased rapidly in Korea in recent years. 
Expenditure is likely to grow further with the policy of expanding NHI coverage for four disease 
areas including cerebrovascular and cardiovascular disease, rare diseases and cancer. 
Consequently, there is a need to analyse the different components leading to this increased 
expenditure as a basis for suggesting future reforms in Korea. 
Objective: Quantify the impact of new and established drugs on the growth of total drug spending 
in South Korea in recent years, specially focusing on the differentiated components of drug 
spending. These include treatment expansion and drug mix effects (switching from cheaper drugs 
to expensive ones and vice versa).  
Materials and Method: A model was proposed and used to assess the impact of both new and 
existing drugs on changes in price, quantity, and drug mix over the 5-year period in Korea from 
2006 to 2010. The database used was the National Health Insurance claims data, which covers 
about 97% of total population of Korea.    
Results: Overall drug spending increased1.43 fold from 2006 to 2010. Drug-mix effect ( =1.32) 
was the main contributing factor to increased drug spending, followed by increased drug 
utilization ( =1.26). For existing drugs, treatment expansion ( ) and drug mix effect ( ) were 
measured at 1.28 and 1.24, respectively, while those of new drugs were 1.02( ) and 1.03( ). 
Therefore, existing drugs have a much greater effect on drug spending than new drugs. 
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According to the Anatomical Therapeutic Classifications, drug spending rose most significantly for 
the ³sensory organs´ class of drugs (   IROORZHG E\ WKH ³YDULRXV´ FODVV  =1.68). For 
existing drugs in the sensory organs class (S), drug mix effect ( ) was measured at 0.96. This 
implies that expensive drugs among existing drugs were replaced by cheaper ones. However, the 
quantity prescribed ( ) substantially increased by 1.88 fold. New drugs within this class that were 
more expensive than existing ones were also prescribed ( =1.09) further increasing drug 
expenditure in Korea.  
Conclusion: We found contrasting results from previous studies. The drug mix effect and existing 
drugs made the largest contribution to drug spending growth rather than new drugs. Policies 
targeting drug mix, such as promoting cost-effective prescription and rational use of drugs, 
including the use of cheaper cost generics without compromising care, should be primarily 
considered to help contain future drug expenditure. 
Keywords : Pharmaceutical expenditure, New drugs, Drug mix, Established drugs, Korea 
 
Key Points 
 Over the last decade, pharmaceutical expenditure has steeply risen in South Korea. Early 
adoption of expensive new drugs and increased consumptions of drugs due to aging populations 
and the high prevalence of chronic diseases have been considered key drivers of cost increase in 
South Korea. 
  A model was suggested and used to quantify the impact of new and established drugs on the 
differentiated components of drug spending including price, quantity and drug mix.  
 The salient findings indicate that drug mix effect (switching cheaper to expensive drugs and vice 
versa) rather than quantity increase was the main factor for the growth of overall drug spending 
between 2006 and 2010. Furthermore, the effects of new drugs were minimal, compared to those 
of existing drugs although they positively affected on the growth of drug spending.  
&RQVHTXHQWO\ it is time to rethink pharmaceutical cost containment policy more focusing on 
rational use of drugs.  
 
Background 
Pharmaceutical expenditure in South Korea is of particular interest to healthcare system 
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regulators. Over the last decade, pharmaceutical expenditure in Korea increased 3.05 fold, while 
total health expenditure increased 2.45 fold [1]. South Korea spent 21.6% of its total healthcare 
expenditure on pharmaceuticals in 2010 [1]. This compares to Organization for Economic 
Cooperation and Development (OECD) countries, which spent approximately 18-19% in 2009 [2]. 
However, in 2010 pharmaceutical expenditure actually fell in 2010 among some EU member 
states [3]. This may be due to a variety of reforms and initiatives including stricter regulations for 
granting premium prices for new drugs and managing their entry, compulsory price cuts for 
existing drugs as well as a range of demand-side measures to enhance the prescribing of low cost 
generics versus premium priced patented products in a class or related class [4-8]. Aging 
populations, the increased prevalence of chronic diseases, early adoption of expensive new 
drugs, and doctors' preference for prescribing high-cost drugs are often cited as explanations for 
the growth of pharmaceutical expenditure in Korea [9-10]. This is set to continue with the policy to 
expand National Health Insurance (NHI) coverage for four disease areas including 
cerebrovascular and cardiovascular disease, rare diseases and cancer, which has been initiated 
by new ruling government, drug expenditure [11]. 
Understanding which factors contribute to increased pharmaceutical expenditure is important to 
the Ministry of Health and Welfare (MOHW) and the National Health Insurance Service (NHIS), 
which are responsible for the financial management of national health insurance. A 
decomposition analysis is often used to identify factors that contribute to the increase in drug 
spending. Drug expenditure is usually broken down into price, quantity, and drug mix using an 
index method, such as Lasyperes, Paasches and )LVKHU¶V Ideal [12-26]. However, this 
methodology has been criticized because it could not show the contribution of new drugs to the 
growth of drug spending on each component of drug spending [24-26]. New drugs are usually 
more expensive than incumbents (existing drugs) and are consequently considered one of key 
drivers of increases in pharmaceutical expenditure [4,26-27]. Switching from cheaper to more 
expensive drugs, the so-called ³GUXJPL[ HIIHFW´ is one of the effects induced by the introduction of 
new drugs. Unless demand-side measures are in place, new premium priced drugs could replace 
cheaper incumbents, increasing the cost of treatment. New drugs can also induce demand from 
those who could not be treated appropriately with existing drug therapies, also referred to as the 
³WUHDWPHQWH[SDQVLRQHIIHFW´>24,26-28].  
In this study, we adopted a modified model of the decomposition analysis to assess the impact of 
new and the established drugs on the dynamics of drug cost, and to identify policy implications for 
drug cost containment. Our analytical approach followed on from the model of Gerdtham and 
colleagues [20-22] and Addis and Magrini [23], but we aim to quantify drug mix effect and 
treatment expansion effect of both new and existing drugs, respectively. The remainder of this 
article is organized as follows: an overview of the Korean pharmaceutical market and the 
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introduction of new drugs; limitations of the decomposition analysis that has been applied in 
previous studies; details of our approach applied in this study; and ending with conclusions drawn 
from our analysis.  
The Korean pharmaceutical market and the introduction of new drugs 
Drug expenditure in Korea has grown steeply following the implementation of the Separation of 
Drug Dispensing and Prescribing (SDP) policy in 2000 [Figure 1]. The market size for 
pharmaceuticals in 2011 was 16,402 trillion Korean Won (KRW) (USD 14.325 billion) and 
pharmaceutical expenditure by National Health Insurance (NHI) amounted to 81.9% of the total 
market [29]. Most medicines available on the market were consumed under the NHI scheme, 
although the number of reimbursable drugs accounted for only 36.8% of all drugs approved by 
Ministry of Food and Drug Safety (MFDS)[Figure 1].  
[Insert Figure 1] 
Most new chemical entities (NCEs) were supplied by multinational companies. Approximately 270 
local companies supplied generic drugs. Few local companies have the potential to develop 
NCEs, and to date only 18 NCEs have been developed by local companies [29]. 
The entry of new drugs is regulated by the Positive List System (PLS) and through price 
negotiations with National Health Insurance Service (NHIS), the single payer. A list of 
reimbursable drugs has been established in accordance with the introduction of the PLS in 2007. 
Subsequently, manufacturers have had to submit new drugs to the MFDS for marketing approval, 
and then to the MOHW to have a drug covered by the NHI. The Drug Reimbursement 
Examination Committee (DREC), part of the Health Insurance Review and Assessment Service 
(HIRA), then makes a final decision. The criteria used to determine reimbursement eligibility for 
new drugs include: clinical usefulness, cost-effectiveness, budget impact, current status of 
reimbursement, and price in other countries [9, 26, 30-32]. Once a drug has been assessed as 
reimbursable, the manufacturer must enter into price negotiations with NHIS before the drug can 
be listed in the formulary. Since 2007, the average number of newly introduced NCEs per year 
has dropped significantly to 27.6, as compared to 36.8 introduced between 2003 and 2006[34].  
Limitations of previous decomposition studies 
Several studies have analyzed drug expenditure by separating it into constituent elements, 
including price and quantity [12-26]. Gerdtham and colleagues [20-22] examined total drug 
expenditure in Sweden, emphasized the importance of residual (in other words ³GUXJ mix´. 
Without changing price and quantity, drug costs can increase as a result of switching from a 
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cheaper drug to an expensive one in a class or related class; this is the so-FDOOHG³GUXJmix´HIIHFW
They pointed out that standard price indices do not reflect price changes resulting from changes 
in drug consumption, especially changes resulting from the introduction of new drugs. Several 
studies have examined drug mix effect and identified it as major factor in drug spending growth 
[20-24]. Dubois and colleagues [25] tried to quantify the impact of new drugs by calculating price 
and volume factors including changes in average price per day, the number of prescriptions per 
person, and the number of days per prescription. Their results indicate that prescribed days, 
prescriptions, and the number of patients were significant factors in expenditure growth. 
According to Gerdtham and colleagues¶ model [20-22], drug mix (residual) and treatment 
expansion effect (quantity increase) were measured. These effects were attributable to both new 
and existing drugs. +RZHYHUSUHYLRXVVWXGLHVGLGQ¶WGLVWLQJXLVKWKHVHHIIHFWV according to types 
of drugs. In this study, we tried to quantify the impact of new drugs on the components of drug cost. 
To do so, we proposed a modified formula to segregate drug mix and treatment expansion effects 
by types of drugs: new and existing drugs. We then applied this formula to investigate the factors 
contributing to increased drug expenditure in the period from 2006 to 2010 in South Korea, and 
quantified the effects of new and existing drugs on changes in each component of drug cost. 
Finally, we have made some suggestions for the authorities to consider when deliberating future 
reforms. These are based on activities successfully undertaken by European health authorities 
and health insurance agencies. 
Materials and Method 
Data collection 
The data used in this study were obtained from the National Health Insurance Service (NHIS), 
which covers about 97% of Korean population. Total pharmaceutical expenditure data from NHIS 
claims for the years from 2006 to 2010 were used. Over 12,000 reimbursable products (about 
4,000 ingredients) were included for analysis. Each ingredient identified in the NHIS data was 
matched to the Anatomical Therapeutic Classification (ATC) code [33]. The data were compiled 
based on ingredients. Medicines that incurred no charges in 2006, but appeared in the data in 
2010 were regarded as new drugs. All other listed drugs were considered incumbents. Quantity 
data was collected as the minimum unit for each drug and delivery system, e.g. ampoules, tablets, 
patches, inhalers and capsules, as it proved impossible to calculate all utilisation in terms of 
defined daily doses.  
Study methodology 
The equation (Equation 1), first proposed by Gerdtham and colleagues [20-22] shows changes in 
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price (P), quantity (Q) and drug mix İThe price change (P) is calculated by Laspeyres index. 
According to this index, the price of new drugs is not detected because their prices are not 
available at the base period. Thus, Laspeyres index (P) reflects only the price of incumbents only. 
The quantity ratio (Q) shows changes in the quantities of prescribed drugs including both new and 
incumbent drugs. Drug mix İ LQGLFDWHV FKDQJHV LQ WKH ZHLJKted average cost of drugs 
attributable to both new and existing ones. Thus, quantity change and drug mix are attributable to 
both new and existing drugs. Consequently, we can measure drug mix and treatment expansion 
effects due to new drugs and existing drugs, separately. 
              (1)
 
NB: Q0: quantity of drugs in 2006; Q1: quantity of drugs in 2010; P0: price of drug in 2006; P1: price of drug in 
2010, Pt : Change in Price, Qt : Change in Quantity, ƃt : Drug mix effect 
 
The following equation is proposed (Equation 2) to identify how new and incumbent drugs affect 
the dynamics of drug cost. The growth of total drug expenditure ( ) is attributed to new drugs ( ) 
and incumbents ( ). 
 
                   (2) 
NB: EN: growth of drug spending on new drugs; EI :growth of drug expenditure on existing drugs; : quantity 
of new drugs in 2010; : price of new drugs in 2010; : quantity of existing drugs in 2006; : quantity of 
existing drugs in 2010; :price of existing drugs in 2006; :price of existing drugs in 2010.  
 
Equation 2 can then be rewritten as Equation 3 and 4: 
                  (3) 
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            (4)                          
NB: Pt: price index between 2006 and 2010; PI : price index of existing drugs; PN : Price index of new drugs; 
Qt : quantity change between 2006 and 2010; QI: quantity change of existing drugs; QN: quantity change of 
new drugs; : drug mix index between 2006 and 2010; :Drug mix index of existing drugs; :Drug mix 
index of new drugs. 
 
 is constituted with  because  is equal to . If > 1, new drugs positively contribute 
to the increase in drug spending. If =1, no impact from new drugs is observed, signifying there 
has been no introduction or penetration of new drugs.  indicates the treatment expansion 
effect of new drugs, and  indicates a shift in prescriptive patterns to expensive new drugs. If one 
of these indices is greater than 1, new drugs positively contributed to the growth of drug spending, 
either by creating demands for new drugs, or by a shift in prescriptive patterns to expensive new 
drugs. This modified equation (Equation 3) can also detect the impact of existing drugs on the 
component of drug cost through .  
Results 
Table 1 presents the quantified impact of new and incumbent drugs on overall drug spending from 
2006 to 2010. Overall pharmaceutical expenditure increased by 43%. Drug mix ( =1.32) was the 
main contributing factor for increased drug spending, followed by quantity increase ( =1.26). The 
price index ( was 0.86, indicating that prices of existing drugs decreased by 14% in 2010, as 
compared to 2006. Existing drugs ( =1.36) rather than new drugs ( =1.05) substantially 
affected the increase in total drug spending. Approximately 83% of the increase in drug 
expenditure was attributable to existing drugs. Quantity ( ) and drug mix ( ) for existing drugs 
increased by 1.24 and 1.28 fold, respectively. This indicates that manufacturers of existing drugs 
have continued to expand their market, and that more expensive drugs have been used rather 
than cheaper alternatives.  
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Table 1. Decomposition analysis for total, incumbent and new drug expenditures 
Category E P Q İ 
Total 1.43 0.86 1.26 1.32 
Incumbents 1.36 0.86 1.24 1.28 
New drugs 1.05 1 1.02 1.03 
 
New drugs have positively contributed to increased drug spending, although minimally compared 
with established drugs. In this regard, 17% of the increase in drug expenditure from 2006 to 2010 
resulted from the use of new drugs.  was set at 1 because the prices of new drugs were not 
available in 2006. Consequently, price changes for new drugs could not be identified within our 
equation. However, the drug-mix effect ( ) induced by new drugs measured 1.03, which 
indicates a switch from incumbents to marginally more expensive new drugs. The impact of new 
drugs on quantity increase ( ) was 1.02, which is not significant. Notably, it was found that the 
treatment expansion and drug mix effects were much larger for existing drugs than for new drugs. 
This is different to the general belief that new drugs are generally regarded as a key driver of 
increased drug expenditure.  
Table 2 presents the results according to ATC codes. Drug spending has risen most significantly 
LQ WKH ³VHQVRU\ RUJDQV´ FODVV RI drugs ( =1.78), IROORZHG E\ WKH ³YDULRXV´ class ( =1.68). 
Increases in expenditure for the various class (V), sensory organs(S), anti-neoplastics & immune 
modulating agents (L), blood and blood forming organs(B), cardiovascular system(C), nervous 
system(N) and respiratory system(R) were greater than the average growth rate (1.42). Growth of 
expenditure for all groups was mainly attributed to incumbent drugs. New drugs influenced 
H[SHQGLWXUHPRVWJUHDWO\IRUWKH³VHQVRU\RUJDQV´FODVV =1.13). No new drugs were launched 
during the observation period for class P (anti-parasitics, insecticides, and repellents). Although 
drug spending for class C drugs increased by 1.53 fold, they represented the greatest percentage 
of total drug spending.  
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Table 2. Growth of drug expenditures for ATC groups 
Anatomical therapeutic class Overall Incumbents New drugs Percentage of TPEa 
(A) Alimentary tract and metabolism 1.37 1.29 1.06 16.3% 
(B) Blood & blood forming organs 1.59 1.54 1.04 9.0% 
(C) Cardiovascular system 1.53 1.44 1.06 19.7% 
(D) Dermatologicals 1.16 1.11 1.05 1.2% 
(G) Genitourinary system and sex hormones 1.39 1.25 1.11 2.4% 
(H) System hormonal preparations 1.36 1.34 1.02 0.8% 
(J) Antiinfective for systemic use 1.25 1.20 1.04 15.1% 
(L) Antineoplastic & immune modulating agents 1.60 1.52 1.05 7.3% 
(M) Musculoskeletal system 1.22 1.17 1.05 7.1% 
(N) Nervous system 1.49 1.41 1.06 9.2% 
(P) Antiparasitics, insecticides & repellents 1.03 1.03 1.00 0.1% 
(R) Respiratory system 1.49 1.42 1.05 5.7% 
(S) Sensory organs 1.78 1.58 1.13 2.6% 
(V) Various 1.68 1.64 1.02 3.5% 
a: Percentage of total pharmaceutical expenditures (TPE) in 2010.   
 
A breakdown of drug expenditure factors for each ATC group, and each type of drug, is presented 
in Table 3. Price indices for all classes are less than 1, indicating a decrease in the prices of 
existing drugs. A major factor in total drug expenditure growth was increased quantities for all 
classes except ATC classes A, J, M, N and R, for which the drug mix effect was a more significant 
factor. Drug mix for all classes increased ( >1) except for class P ( =0.86). The effects of new 
drugs equalled 1 for ATC class P. This indicates that cheaper drugs in ATC class P were used 
instead of expensive ones, without the introduction of new drugs. For ATC class S, cheaper 
existing drugs replaced more expensive ones (  =0.96), but the quantity ( ) increased 
substantially (1.88 times). New drugs within this class, which were more expensive than 
incumbents, were introduced and prescribed (  =1.09), which led to the increase in overall drug 
expenditure. Cheaper anti-parasitic drugs were increasingly used ( =0.86) without the 
introduction of new drugs. For ATC class S, drug quantities substantially increased ( =1.88) and 
cheaper existing drugs were frequently used ( =0.96). In addition, expensive new drugs were 
introduced ( =1.03 and =1.02). Overall, these factors contributed to an increase in drug 
spending.  
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Table 3 Growth of drug expenditures for ATC groups  
Anatomical therapeutic class Total Incumbents New drugs 
P Q İ P Q İ Q İ 
(A) Alimentary tract and metabolism 0.88 1.16 1.34 0.88 1.15 1.28 1.01 1.05 
(B) Blood & blood forming organs 0.88 1.50 1.20 0.88 1.43 1.22 1.05 0.98 
(C) Cardiovascular system 0.84 1.50 1.22 0.84 1.44 1.19 1.04 1.02 
(D) Dermatologicals 0.86 1.26 1.07 0.86 1.24 1.04 1.02 1.03 
(G) Genitourinary system and sex hormones 0.76 1.42 1.29 0.76 1.30 1.27 1.09 1.01 
(H) System hormonal preparations 0.83 1.39 1.18 0.83 1.38 1.16 1.00 1.01 
(J) Antiinfective for systemic use 0.85 1.13 1.30 0.85 1.13 1.25 1.00 1.04 
(L) Antineoplastic & immune modulating agents 0.84 1.54 1.23 0.84 1.54 1.18 1.00 1.05 
(M) Musculoskeletal system 0.87 1.12 1.26 0.87 1.11 1.21 1.01 1.04 
(N) Nervous system 0.87 1.18 1.45 0.87 1.17 1.39 1.01 1.04 
(P) Antiparasitics, insecticides & repellents 0.91 1.31 0.86 0.91 1.31 0.86 1.00 1.00 
(R) Respiratory system 0.89 1.26 1.32 0.89 1.23 1.29 1.03 1.02 
(S) Sensory organs 0.88 1.94 1.04 0.88 1.88 0.96 1.03 1.09 
(V) Various 0.90 1.46 1.27 0.90 1.46 1.25 1.00 1.02 
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Discussion 
This study was initiated to assess the impact of new drugs as a driver of increase drug 
expenditure in Korea in recent years. The treatment expansion and drug-mix effects of new drugs 
were examined. To quantify these effects, we analyzed total pharmaceutical expenditure for 
South Korea over the 5-year period from 2006 to 2010. Previous studies [20-24] considered only 
changes in price, quantity, and drug mix over time, without segregating observed changes by type 
of drug. However, these changes were attributable to both new drugs and existing drugs. Our 
research question was posed to distinguish the effects associated with new and existing drugs. 
The previous model of Gerdtham and colleagues [20-22] was modified to calculate the treatment 
expansion effect ( ) and drug-mix effect ( ). The equation (Equation 3) was also designed to 
measure the impact of existing drugs in light of changes in price ( , quantity ( ) and drug mix 
( ).  
The results of this study indicate that existing drugs had a greater effect on the growth of drug 
expenditure in recent years in Korea than the launch of new premium priced drugs. Although 
treatment expansion and the drug-mix effect of new drugs positively contributed to the increase in 
drug spending, the quantified impact was minimal. Existing drugs substantially contributed to 
increased pharmaceutical expenditure in recent years. Prices for existing drugs decreased 
slightly over the period ( =0.86), but the drug-mix effect ( =1.32) had the most significant impact, 
followed by quantity increase ( =1.26). Given that increased drug volumes have long been 
claimed to be the major factor contributing to the growth of Korean pharmaceutical expenditure in 
recent years [17-19], this study presents different results. Our findings indicate that the drug-mix 
effect, both for existing and new drugs, had a greater impact on the growth of drug expenditure 
than increased volumes. Additionally, the growth of expenditure was mainly attributable to 
existing drugs rather than new drugs. Prices for existing drugs decreased in 2010 in all ATC 
classes when compared to 2006 prices. However, the overall drug-mix changed in a number of 
classes increasing overall drug expenditure. The drug mix effect was more significant for ATC 
classes A, J, M, N and R, with increasing volumes the major factor for increased drug expenditure 
in the other classes. This is perhaps not surprising since cost containment measures for 
pharmaceuticals in South Korea have traditionally focused on enforced price cuts rather than 
demand-side measures. Numerous re-pricing strategies have been implemented, but the price 
decreases over the 5 years have not been significant [32, 34-35]. The absence of policies that 
encourage the use of cheaper drugs or more cost-effective prescriptive practices results in the 
increase utilization of expensive drugs facilitated by the considerable marketing activities of 
pharmaceutical companies [36]. Therefore, demand-side strategies to address this should be 
prioritized in order to efficiently control the increase of pharmaceutical expenditure in Korea with 
increased coverage in four disease areas.  
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Several policies enacted by the NHIS targeting new drugs, such as the PLS and price negotiation 
procedure with the single payer, have acted as an entry barrier. However, many of the strategies 
for drugs that are already listed have focused only on cutting prices, and the effectiveness of 
these strategies is debatable [37]. Since our findings suggest that existing drugs rather than new 
drugs have a significant impact on the growth of drug expenditure, policies targeting both 
cost-effective prescription practices and efficient price controls for existing drugs should be 
considered. There have been a number of supply- and demand-side measures across Europe to 
enhance the prescribing of low cost generics in classes where all the drugs are seen as similar in 
all or nearly all patients [38-42].  These initiatives have released considerable resources without 
compromised care (summarized in Table 4), with the products in these classes seen as 
therapeutically similar at appropriate doses demonstrated by meta analyses, registry studies as 
well as successful therapeutic switching programs [47-53].    
A similar finding regarding losartan in Sweden was seen in NHS Bury in England. Initially there 
was no change in the utilization of losartan post generics. This changed significantly following 
multiple interventions which were similar to Sweden (Table 4) for patients with hypertension, with 
losartan utilisation increasing significantly from 26% of all single ARBs to 65% 7 months later [49]. 
The savings were estimated at eight times the cost of implementing this comprehensive program 
[49]. 
 
Table 4. Combination of supply- and demand-side initiatives among selected European countries and 
their impact 
Country Class Initiative and outcomes 
Denmark 
[42] 
ARBs x Delisting of all other ARBs other than losartan from the reimbursed 
list 
x Patients could still be prescribed another ARB and have this 
reimbursed. However, the prescribing physician has to justify the 
rationale and have this accepted before other ARBs reimbursed ± 
otherwise 100% co-payment 
x The combination of supply- and demand-side measures in Denmark 
resulted in a 77% reduction in ARB expenditure over the study period 
despite a 16% increase in utilisation, leading to estimated savings of 
RYHUPLOOLRQ'DQLVK.URQHU¼PLOOLRQSHUDQQXP 
Netherlands  
[38, 41,43] 
PPIs and 
statins 
x Under the preference pricing policies only the cheapest generics are 
reimbursed, with patients having to cover the costs themselves for a 
non-preferred drug. This has resulted in generic omeprazole and 
simvastatin a only 2% of pre-patent loss prices  
x This coupled with extensive multiple demand side measures 
including educational activities, prescribing targets and physicians 
financial incentives, to increase the prescribing of generics vs. 
patented products resulted in reimbursed expenditure for the PPIs 
falling by 58% in 2010 vs. 2000 despite a 3 fold increase in utilisation 
(DDDs) and reimbursed expenditure for the statins falling by 14% in 
13 
2010 vs. 2000 despite a 3.8 fold increase in utilisation. As a result, 
saving considerable resources without compromising care  
Scotland 
[38,40,41, 
44,45] 
PPIs, statins 
and ACEIs 
vs. ARBs 
o Transparency in the pricing of generics, coupled with transparency in 
the rebates offered to wholesalers and pharmacists, has resulted in 
prices of high volume generics as low as 2%/ 3% to 12% of 
pre-patent loss prices 
o Multiple demand-side measures including extensive educational 
activities, prescribing targets and physician financial incentive 
schemes to increase the prescribing of generics vs. patented 
products resulted in expenditure/ 1000 inhabitants/year for the PPIs 
in 2010 56% below 2001 levels despite a 3 fold increase in utilisation 
and reimbursed expenditure for the statins increased by only 7% in 
2010 compared with 2001 despite a 6.2 fold increase in utilisation. 
Without these measures, health authority spending on PPIs for the 
same overall utilization would have been GB£159million higher in 
2010 in Scotland for the 5.2million population and GB£290million for 
the statins 
o Similar multiple demand-side measures vs. Portugal with its limited 
demand-side measures to encourage the preferential prescribing of 
generic ACEIs limited ARB prescribing to only 19% of total 
renin-angiotensin inhibitor drugs in 2007 (DDD basis) vs. 44% in 
Portugal, leading to stable reimbursed expenditure between 2001 
and 2007 vs. over 40% increase in Portugal 
Sweden 
[38,39,41, 
46-48] 
PPIs, statins 
and ARBs 
x Compulsory generic substitution with the lowest price molecule has 
resulted in prices for high-volume generics being 4 to 13% of 
originator pre-patent loss prices by 2009. More recently:  
o all pharmacies are obligated to offer patients the cheapest 
molecule currently on the market (ATC Level 5) when there 
are substitutable generic medicines available 
o there are regular monthly auctions for generics in Sweden, 
with the manufacturer with the lowest price wining the 
auction. However manufacturers must be able to supply the 
whole market for the entire period (typically 70% to 80% of 
sales during the period) 
o Expected savings from the tendering process are estimated 
at 8billion SEK/ year from 2011 onwards 
x Multiple demand side measures including extensive educational 
activities, prescribing targets and physician financial incentives, to 
increase the prescribing of generics resulted in reimbursed 
expenditure for the PPIs decreasing by 49% in 2007 vs. 2001 despite 
utilisation increasing by 53% during this period. Similar combined 
measures led to a 39% reduction in statin expenditure in 2007 vs. 
2001 idespite a 3.2 fold increase in utilisation during this period 
x Reimbursed expenditure (Euros/ 1000 inhabitants/ year) in Sweden 
was less than one-tenth of that in Ireland in 2007 with its increased 
utilisation of patented PPIs and statins following generics as limited 
demand-side measures to combat company activities (although 
more co-morbid population) 
x Similar demand-side measures including encouraging therapeutic 
substitution of patented ARBs with losartan significantly increased 
losartan utilisation in recent years. As a result, total single ARB 
expenditure fell by 26% in recent years in Sweden despite a 16% 
increase in utilisation. Separate analyses suggest care was not 
compromised at appropriate ARB doses 
NB: ARB = angiotensin receptor blocker, ACEIs = Angiotensin converting enzyme inhibitors, PPIs = Proton 
Pump Inhibitors 
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We believe the exemplars in Denmark, the Netherlands, Sweden and the UK (NHS Bury and 
Scotland) among a range of classes provide guidance for Korea as it contemplates abolishing 
co-payments in high prevalence disease areas such as cardiovascular and cerebrovascular 
diseases without appreciably increasing expenditures. 
We accept there are limitations with the study design. These include our suggested methodology. 
However, we believe this approach is justified for the reasons we have given. We also accept that 
we have not used defined daily doses in our analysis. However, other studies have used different 
units including IMS units [54] as well as items dispensed [49]. Consequently, we believe our 
findings are justified and provide direction to the authorities in Korea. 
Conclusions 
This study used a model to assess the impact of both new and existing drugs on changes in price, 
quantity, and drug mix over the 5-year period in Korea from 2006 to 2010. Contrary to the results 
of previous studies, our findings indicate that the drug-mix effect and existing drugs contributed 
most to the growth of pharmaceutical expenditure. Policies targeting drug mix are not sufficiently 
implemented in South Korea and reforms to encourage the prescribing use of cost-effective drugs 
within a class should be emphasized. Measures can also include initiatives to reduce drug 
volumes where these are considered inappropriately high. 
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